CLINICAL_TRIALS
trial_result
· 2022-12-01
Clinical Trial Update: Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) [Phase 3]
Summary
Phase 3 trial update on a 3-dose V114 regimen in healthy infants assessing safety, tolerability, and immunogenicity; results posted after completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2022-12-01